Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: A prospective, multicenter, observational study

T. H. Kim, H. W. You, J. H. Park, Jeong Gu Lee, M. S. Choo, W. H. Park, J. Z. Lee, C. H. Park, Y. G. Na, D. D. Kwon, K. S. Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Summary Objectives The aim of this study was to evaluate the persistence with solifenacin therapy over a 12-month period in patients with overactive bladder (OAB). Methods This is a 52-week long, multicenter, prospective, observational study. The subjects were individuals ≥ 18 years old with OAB symptoms for ≥ 3 months, characterised by a total OAB Symptom Score (OABSS) of ≥ 3 and OABSS urgency item score of ≥ 2. Patients were prescribed 5 mg or 10 mg of solifenacin once daily for OAB symptoms. Drug persistence, reasons for discontinuation and factors related to the persistence were evaluated. Results A total of 1018 patients (329 men, 689 women) with a mean age of 59 years were included. The 52-week drug persistence rate was 22.1%. The drug persistence rates at 12, 24 and 36 weeks were 72.4%, 45.8% and 31.1% respectively. The three most common reasons for discontinuing therapy included symptom improvement in 30.4%, lack of efficacy in 13.4%, and a switch to another antimuscarinic agent in 10.8%. Older patients (odds ratio = 1.02, 95% CI: 1.01-1.04), and female patients (odds ratio = 1.94, 95% CI: 1.37-2.75) were more likely to continue the medication over the 12-month period than were younger, male patients. The number of nocturia episodes was negatively correlated with drug persistence (odds ratio = 0.83, 95% CI: 0.71-0.97). Conclusions There was low persistence (22%) to solifenacin therapy for OAB symptoms over a 12-month period. Older patients, female patients and those with fewer episodes of nocturia were more persistent to therapy than were others.

Original languageEnglish
Pages (from-to)351-357
Number of pages7
JournalInternational Journal of Clinical Practice
Volume70
Issue number4
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

Overactive Urinary Bladder
Multicenter Studies
Observational Studies
Nocturia
Odds Ratio
Therapeutics
Pharmaceutical Preparations
Muscarinic Antagonists
Solifenacin Succinate
Prospective Studies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting : A prospective, multicenter, observational study. / Kim, T. H.; You, H. W.; Park, J. H.; Lee, Jeong Gu; Choo, M. S.; Park, W. H.; Lee, J. Z.; Park, C. H.; Na, Y. G.; Kwon, D. D.; Lee, K. S.

In: International Journal of Clinical Practice, Vol. 70, No. 4, 01.04.2016, p. 351-357.

Research output: Contribution to journalArticle

Kim, T. H. ; You, H. W. ; Park, J. H. ; Lee, Jeong Gu ; Choo, M. S. ; Park, W. H. ; Lee, J. Z. ; Park, C. H. ; Na, Y. G. ; Kwon, D. D. ; Lee, K. S. / Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting : A prospective, multicenter, observational study. In: International Journal of Clinical Practice. 2016 ; Vol. 70, No. 4. pp. 351-357.
@article{97d692140c544e9c880ebbaf5ecabc69,
title = "Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: A prospective, multicenter, observational study",
abstract = "Summary Objectives The aim of this study was to evaluate the persistence with solifenacin therapy over a 12-month period in patients with overactive bladder (OAB). Methods This is a 52-week long, multicenter, prospective, observational study. The subjects were individuals ≥ 18 years old with OAB symptoms for ≥ 3 months, characterised by a total OAB Symptom Score (OABSS) of ≥ 3 and OABSS urgency item score of ≥ 2. Patients were prescribed 5 mg or 10 mg of solifenacin once daily for OAB symptoms. Drug persistence, reasons for discontinuation and factors related to the persistence were evaluated. Results A total of 1018 patients (329 men, 689 women) with a mean age of 59 years were included. The 52-week drug persistence rate was 22.1{\%}. The drug persistence rates at 12, 24 and 36 weeks were 72.4{\%}, 45.8{\%} and 31.1{\%} respectively. The three most common reasons for discontinuing therapy included symptom improvement in 30.4{\%}, lack of efficacy in 13.4{\%}, and a switch to another antimuscarinic agent in 10.8{\%}. Older patients (odds ratio = 1.02, 95{\%} CI: 1.01-1.04), and female patients (odds ratio = 1.94, 95{\%} CI: 1.37-2.75) were more likely to continue the medication over the 12-month period than were younger, male patients. The number of nocturia episodes was negatively correlated with drug persistence (odds ratio = 0.83, 95{\%} CI: 0.71-0.97). Conclusions There was low persistence (22{\%}) to solifenacin therapy for OAB symptoms over a 12-month period. Older patients, female patients and those with fewer episodes of nocturia were more persistent to therapy than were others.",
author = "Kim, {T. H.} and You, {H. W.} and Park, {J. H.} and Lee, {Jeong Gu} and Choo, {M. S.} and Park, {W. H.} and Lee, {J. Z.} and Park, {C. H.} and Na, {Y. G.} and Kwon, {D. D.} and Lee, {K. S.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1111/ijcp.12783",
language = "English",
volume = "70",
pages = "351--357",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting

T2 - A prospective, multicenter, observational study

AU - Kim, T. H.

AU - You, H. W.

AU - Park, J. H.

AU - Lee, Jeong Gu

AU - Choo, M. S.

AU - Park, W. H.

AU - Lee, J. Z.

AU - Park, C. H.

AU - Na, Y. G.

AU - Kwon, D. D.

AU - Lee, K. S.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Summary Objectives The aim of this study was to evaluate the persistence with solifenacin therapy over a 12-month period in patients with overactive bladder (OAB). Methods This is a 52-week long, multicenter, prospective, observational study. The subjects were individuals ≥ 18 years old with OAB symptoms for ≥ 3 months, characterised by a total OAB Symptom Score (OABSS) of ≥ 3 and OABSS urgency item score of ≥ 2. Patients were prescribed 5 mg or 10 mg of solifenacin once daily for OAB symptoms. Drug persistence, reasons for discontinuation and factors related to the persistence were evaluated. Results A total of 1018 patients (329 men, 689 women) with a mean age of 59 years were included. The 52-week drug persistence rate was 22.1%. The drug persistence rates at 12, 24 and 36 weeks were 72.4%, 45.8% and 31.1% respectively. The three most common reasons for discontinuing therapy included symptom improvement in 30.4%, lack of efficacy in 13.4%, and a switch to another antimuscarinic agent in 10.8%. Older patients (odds ratio = 1.02, 95% CI: 1.01-1.04), and female patients (odds ratio = 1.94, 95% CI: 1.37-2.75) were more likely to continue the medication over the 12-month period than were younger, male patients. The number of nocturia episodes was negatively correlated with drug persistence (odds ratio = 0.83, 95% CI: 0.71-0.97). Conclusions There was low persistence (22%) to solifenacin therapy for OAB symptoms over a 12-month period. Older patients, female patients and those with fewer episodes of nocturia were more persistent to therapy than were others.

AB - Summary Objectives The aim of this study was to evaluate the persistence with solifenacin therapy over a 12-month period in patients with overactive bladder (OAB). Methods This is a 52-week long, multicenter, prospective, observational study. The subjects were individuals ≥ 18 years old with OAB symptoms for ≥ 3 months, characterised by a total OAB Symptom Score (OABSS) of ≥ 3 and OABSS urgency item score of ≥ 2. Patients were prescribed 5 mg or 10 mg of solifenacin once daily for OAB symptoms. Drug persistence, reasons for discontinuation and factors related to the persistence were evaluated. Results A total of 1018 patients (329 men, 689 women) with a mean age of 59 years were included. The 52-week drug persistence rate was 22.1%. The drug persistence rates at 12, 24 and 36 weeks were 72.4%, 45.8% and 31.1% respectively. The three most common reasons for discontinuing therapy included symptom improvement in 30.4%, lack of efficacy in 13.4%, and a switch to another antimuscarinic agent in 10.8%. Older patients (odds ratio = 1.02, 95% CI: 1.01-1.04), and female patients (odds ratio = 1.94, 95% CI: 1.37-2.75) were more likely to continue the medication over the 12-month period than were younger, male patients. The number of nocturia episodes was negatively correlated with drug persistence (odds ratio = 0.83, 95% CI: 0.71-0.97). Conclusions There was low persistence (22%) to solifenacin therapy for OAB symptoms over a 12-month period. Older patients, female patients and those with fewer episodes of nocturia were more persistent to therapy than were others.

UR - http://www.scopus.com/inward/record.url?scp=84962425383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962425383&partnerID=8YFLogxK

U2 - 10.1111/ijcp.12783

DO - 10.1111/ijcp.12783

M3 - Article

C2 - 27028673

AN - SCOPUS:84962425383

VL - 70

SP - 351

EP - 357

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 4

ER -